4HEINO STASS.Pharmacokinetics,safety and tolerability of moxifloxacin[J]. Clin Pharmacokinet,2001,40(Suppl 1):1-9.
二级参考文献25
1Pong A, Thomson KS, Moland ES, et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin[J]. J Antimicrob Chemother, 1999,44(5):621-627
2Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: Clinical efficacy and safety[J]. Am J Health Syst Pharm, 2001,58(5):379-388
3Wise R, Andrews JM, Marshall G, et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration[J]. Antimicrob Agents Chemother, 1999,43(6):1508-1510
4Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man[J]. J Antimicrob Chemother, 1999,443(Suppl B):83-90
5Baz MN, Jannetti W, Villanueva C, et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis[J]. Todays Ther Trends, 1999,17(2):303-319
6Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis[J]. Clin Ther , 1999, 21(10):1664-1677
7Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis[J]. Respir Med, 2000,94(1):18-27
8Mathew CP, Warner JH, Heyd A, et al. Short course moxifloxacin vs azithromycin in the treatment of acute exacerbation of chronic bronchitis(A). American Thoracic Society International Meeting(C). Toronto, 2000 (May): 5-10
9Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis[J]. J Antimicrob Chemother, 1999, 44(4):501-513
10Patel T, Pearl J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400mg once daily in the treatment of patients with community-acquired pneumonia[J]. Respir Med, 2000, 94(2):97-105
2Zhanel GG, Noreddin AM.Pharmacokinetics and pharmacodynamics of the new fluoroquinolones:focus on respiratory infections [J].Curr Opin Pharmacol, 2001, 1(5):459.
3Dean H,Timothy B.Short-course(5-day)moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis[J].Today's Therapeutic Trent,2001,19(4):117-136.
4Honeylourne D, Baner jee D, Andrews J, et al. Concentrations of gatifloxacin in plasma. and pulmonary compartments following a single 400rug oral in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother, 2001, 48(1) :63.
5Mitsuyoshi N, Toshihiko U, Kazuhiro K, et al. Singleand multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother, 1995, 39(12) :2635.
65HEINOSTASS.Pharmackinetics,safety and toler-ability of moxifoxacin. Ctinpharmacorinet, 2001,40( 11 ) : 1.
